PBAC submission: subcutaneous ocrelizumab

MS Australia is writing to the Pharmaceutical Benefits Advisory Committee (PBAC) in support of the request to include ocrelizumab (Ocrevus®) via subcutaneous (SC) delivery on the Pharmaceutical Benefits Scheme (PBS) for the treatment of people living with relapsing-remitting multiple sclerosis (RRMS).

<meta http-equiv="refresh" content="0; URL=https://www.msaustralia.org.au/wp-content/uploads/pbac-submission_ocrelizumab-sc_msa_final.pdf" />

Read More

Newsletter subscription

  • Enter your details

PBAC submission: subcutaneous ocrelizumab